HEALTHCARE (NY:XLV)

158.10 -2.09 (-1.31%)

Streaming Delayed Price Updated: 12:31 PM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2 3 4 5 6 7 8 9

...

42 43 Next >

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Via MarketMinute

Topics Artificial Intelligence ETFs

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗

February 26, 2026

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Via Stocktwits

Topics Artificial Intelligence

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗

February 26, 2026

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.

Via Stocktwits

Topics Artificial Intelligence

BSX Stock Tumbles Pre-Market On Softer 2026 Sales Growth Forecast ↗

February 04, 2026

Via Stocktwits

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗

January 22, 2026

Via Stocktwits

TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally ↗

January 15, 2026

Via Stocktwits

Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? ↗

February 25, 2026

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

Via Stocktwits

Why Did IXHL Stock Tank Over 32% Today? ↗

February 25, 2026

The company’s board approved a 1-for-30 reverse stock split, effective on February 26.

Via Stocktwits

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗

February 24, 2026

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

Via Stocktwits

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

Via Stocktwits

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? ↗

January 12, 2026

Via Stocktwits

Why Did IOVA Stock Gain Pre-Market Today? ↗

February 24, 2026

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

Via Stocktwits

Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗

February 20, 2026

Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.

Via Stocktwits

Why Did INTS Stock Plummet 30% Pre-Market Today? ↗

February 13, 2026

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.

Via Stocktwits

Why Did IMUX Stock Surge 33% Pre-Market Today? ↗

February 13, 2026

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.

Via Stocktwits

Sector Alert: 4 Healthcare ETFs Poised for Explosive Growth Now ↗

February 11, 2026

Healthcare stocks have lagged the market for years, but 2026 is looking much better.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility ↗

February 09, 2026

Via MarketBeat

Topics ETFs

LLY Stock Climbs Pre-Market On $2.4 Deal To Acquire Orna Therapeutics ↗

February 09, 2026

The acquisition will strengthen Lilly’s pipeline with a new class of therapies built on engineered circular RNA and proprietary lipid nanoparticles.

Via Stocktwits

Harel Insurance Sold $330 Million of Invesco KBW Bank ETF ↗

February 05, 2026

Invesco KBW Bank ETF tracks a benchmark of major U.S. banking institutions, offering targeted sector exposure and a moderate yield.

Via The Motley Fool

Topics ETFs Regulatory Compliance

UNH Stock Craters To 6-Month Low: Piper Sandler Still Sees 40% Upside, Would Buy The Dip ↗

January 28, 2026

UnitedHealth expects some membership contraction in 2026 and noted that CMS’s Medicare rate “simply doesn't reflect the reality.”

Via Stocktwits

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗

January 27, 2026

Altimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk.

Via Stocktwits

INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally? ↗

January 26, 2026

According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund.

Via Stocktwits

Topics Artificial Intelligence

Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗

January 26, 2026

Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.”

Via Stocktwits

The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare

January 23, 2026

The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy

Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗

January 22, 2026

In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.

Via Stocktwits

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD ↗

January 16, 2026

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

Via Stocktwits

Topics Artificial Intelligence ETFs

Nano-Cap Regentis Biomaterials Stock Is Up Nearly 15% This Year: Why Retail Traders Are Swarming It ↗

January 16, 2026

Heading to close this week as its best week since IPO, RGNT has become a retail favorite with surging followers on Stocktwits.

Via Stocktwits

Topics Initial Public Offering Intellectual Property

MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab ↗

January 15, 2026

The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials.

Via Stocktwits

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? ↗

January 14, 2026

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

Via Stocktwits

Topics Artificial Intelligence

Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains ↗

January 07, 2026

Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.

Via Stocktwits

Topics Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 9

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.